8-K filing — IMPACT BIOMEDICAL INC. (IBO)
Filed: 2026-10-09 AccNo: 0001493152-26-046572 Size: 2 MB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Impact BioMedical Announces 1-For-12.62 Reverse Stock Split, Reducing Shares Outstanding From ~107.8M To ~8.54M, Effective Sept. 23
Impact BioMedical Inc. (the "Company") today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
Impact Biomedical Inc (NYSE: IBO) announced a 1 for 12.62 reverse stock split effective September 23, 2026, to support its proposed merger with Zoar Limited. The merger exchange ratio was corrected to 1 share of Zoar for every 1 share of Impact stock (post-split). Upon completion, the combined entity will focus on developing and supplying Active Pharmaceutical Ingredients for special therapeutic areas.